NVAX Novavax Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * EVANS GARY C	2. Issuer Name and Ticker or Trading Symbol NOVAVAX INC [ NVAX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 8/18/2020
(Street) GAITHERSBURG, MD 20878 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 8/20/2020	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								16099 (1)	D
Common Stock								625 (1)(2)	I	By Evans 1997 Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	This amendment to the original Form 4 filed on August 20, 2020 is being filed to correct the amounts of securities beneficially owned by the reporting person to reflect the 1-for-20 reverse stock split of Novavax, Inc. on May 10, 2019. The amounts of securities beneficially owned by the reporting person reported in Column 5 of Table I of the original Form 4 were inadvertently reported on a pre-split basis. The amounts shown in Column 5 of Table I of this amendment reflect the amounts that should have been reported in Column 5 of Table I of the original Form 4 following all transactions reported therein, after taking into account the reverse stock split.
(2)	The reporting person no longer has a reportable beneficial interest in shares previously reported as owned of record by Gary Evans Custodian for Dustin Evans UTMA/TX or shares previously reported as owned of record by Gary Evans Custodian for Casey Evans UTMA/TX. The reporting person indirectly beneficially owns 625 shares held by Evans 1997 Trust since 1997, which were inadvertently omitted from previous filings.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
EVANS GARY C C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD GAITHERSBURG, MD 20878	X

Signatures
/s/ John A. Herrmann III, Attorney-in-Fact		9/4/2020
**Signature of Reporting Person		Date